Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trialRaches Ella, Krishna Mohan Vadrevu|The Lancet Infectious Diseases|2021Cited by 364
Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up reportRaches Ella, Krishna Mohan Vadrevu|medRxiv|2020Cited by 38